title: Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
abstract: Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades and has been accepted as an effective therapeutic modality in the treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs) or neuroendocrine tumors (NETs). The two most commonly used radiopeptides for PRRT, (90)Y-octreotide and (177)Lu-octreotate, produce disease-control rates of 68%-94%, with progression-free survival rates that compare favorably with chemotherapy, somatostatin analogues, and newer targeted therapies. In addition, biochemical and symptomatic responses are commonly observed. In general, PRRT is well tolerated with only low to moderate toxicity in most individuals. In line with the need to place PRRT in the therapeutic sequence of gastroenteropancreatic NENs, a recently sponsored phase III randomized trial in small intestine NENs treated with (177)Lu-octreotate vs high-dose octreotide long-acting release demonstrated that (177)Lu-octreotate significantly improved progression-free survival. Other strategies that are presently being developed include combinations with targeted therapies or chemotherapy, intra-arterial PRRT, and salvage treatments. Sophisticated molecular tools need to be incorporated into the management strategy to more effectively define therapeutic efficacy and for an early identification of adverse events. The strategy of randomized controlled trials is a key issue to standardize the treatment and establish the position of PRRT in the therapeutic algorithm of NENs.
authors.affiliation: Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy; LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka. Electronic address: lisa.bodei@ieo.it.
authors.forename: Lisa
authors.initials: L
authors.lastname: Bodei
authors.affiliation: LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka; Nuclear Medicine Department, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Dik J
authors.initials: DJ
authors.lastname: Kwekkeboom
authors.affiliation: Wren Laboratories, Branford, CT.
authors.forename: Mark
authors.initials: M
authors.lastname: Kidd
authors.affiliation: LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka; Department of Gastroenterological Surgery, Yale School of Medicine, New Haven, CT.
authors.forename: Irvin M
authors.initials: IM
authors.lastname: Modlin
authors.affiliation: LuGenIum Consortium, Milan, Rotterdam, London, Bad Berka; Wren Laboratories, Branford, CT.
authors.forename: Eric P
authors.initials: EP
authors.lastname: Krenning
mesh_terms: D006801:Humans; D018358:Neuroendocrine Tumors / Q000378:metabolism / Q000532:radiotherapy; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D017481:Receptors, Somatostatin / Q000378:metabolism; D012449:Safety; D013004:Somatostatin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: D017481:Receptors, Somatostatin; D013004:Somatostatin